A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT06087289 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: KAND567
DRUG: Carboplatin

Sponsor

Novakand Pharma AB

Collaborators

[object Object]